Non-Invasive Prenatal Test (NIPT) is a screening test from mother’s blood which have the presence of small amounts of baby’s DNA (known as cell-free DNA, or cfDNA) as early as ten weeks of gestation. The rapid development of next generation sequencing technology makes it possible to detect the risk of having chromosomal abnormalities including Down Syndrome, Patau Syndrome, Edwards Syndrome, and other genetic conditions non-invasively.

Placental blood in the baby’s umbilical cord has a rich source of HEMATOPOETIC STEM CELLS (HSCs), which are blood-forming stem cells. Hematopoietic stem cells can be used in therapy for more than 80 types of diseases.